86 related articles for article (PubMed ID: 14966084)
21. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.
Greco FA; Bonomi P; Crawford J; Kelly K; Oh Y; Halpern W; Lo L; Gallant G; Klein J
Lung Cancer; 2008 Jul; 61(1):82-90. PubMed ID: 18255187
[TBL] [Abstract][Full Text] [Related]
22. A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in Phase I trials.
Gönen M
Contemp Clin Trials; 2005 Apr; 26(2):131-40. PubMed ID: 15837436
[TBL] [Abstract][Full Text] [Related]
23. Dose-finding approach for dose escalation with overdose control considering incomplete observations.
Mauguen A; Le Deley MC; Zohar S
Stat Med; 2011 Jun; 30(13):1584-94. PubMed ID: 21351289
[TBL] [Abstract][Full Text] [Related]
24. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
[TBL] [Abstract][Full Text] [Related]
25. Escalation with overdose control for phase I drug-combination trials.
Shi Y; Yin G
Stat Med; 2013 Nov; 32(25):4400-12. PubMed ID: 23630103
[TBL] [Abstract][Full Text] [Related]
26. A new screening model for safety evaluation of superantigen-antibody recombinant fusion proteins (mAb Fab-SEA/E) using telemetric monitoring in conscious rabbits.
Ilbäck NG; Persson R; Gunnarsson K; Stålhandske T
J Pharmacol Toxicol Methods; 2002; 48(1):31-9. PubMed ID: 12750039
[TBL] [Abstract][Full Text] [Related]
27. Overview of clinical trials employing antibody-targeted superantigens.
Persson B; Persson R; Weiner LM; Alpaugh RK
Adv Drug Deliv Rev; 1998 Apr; 31(1-2):143-152. PubMed ID: 10837622
[TBL] [Abstract][Full Text] [Related]
28. Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials.
Wheeler GM; Sweeting MJ; Mander AP
Stat Med; 2017 Jul; 36(16):2499-2513. PubMed ID: 28295513
[TBL] [Abstract][Full Text] [Related]
29. Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials.
Chen Z; Yuan Y; Li Z; Kutner M; Owonikoko T; Curran WJ; Khuri F; Kowalski J
Contemp Clin Trials; 2015 Jul; 43():133-41. PubMed ID: 26012358
[TBL] [Abstract][Full Text] [Related]
30. Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.
Chen Z; Tighiouart M; Kowalski J
Contemp Clin Trials; 2012 Sep; 33(5):949-58. PubMed ID: 22561391
[TBL] [Abstract][Full Text] [Related]
31. Patient specific dosing in a cancer phase I clinical trial.
Babb JS; Rogatko A
Stat Med; 2001 Jul; 20(14):2079-90. PubMed ID: 11439422
[TBL] [Abstract][Full Text] [Related]
32. Bayesian dose escalation with overdose and underdose control utilizing all toxicities in Phase I/II clinical trials.
Tu J; Chen Z
Biom J; 2024 Jan; 66(1):e2200189. PubMed ID: 38047521
[TBL] [Abstract][Full Text] [Related]
33. Effects of a superantigen-antibody recombinant fusion protein (r-C242 Fab-SEA) on toxicological responses in the anaesthetised rabbit.
Ilbäck NG; Gunnarsson K; Persson R; Lindh U; Stålhandske T
Toxicology; 2003 Mar; 185(1-2):161-74. PubMed ID: 12505454
[TBL] [Abstract][Full Text] [Related]
34. Exposure driven dose escalation design with overdose control: Concept and first real life experience in an oncology phase I trial.
Micallef S; Sostelly A; Zhu J; Baverel PG; Mercier F
Contemp Clin Trials Commun; 2022 Apr; 26():100901. PubMed ID: 35198796
[TBL] [Abstract][Full Text] [Related]
35. Escalation with overdose control using time to toxicity for cancer phase I clinical trials.
Tighiouart M; Liu Y; Rogatko A
PLoS One; 2014; 9(3):e93070. PubMed ID: 24663812
[TBL] [Abstract][Full Text] [Related]
36. Adaptive Estimation of Personalized Maximum Tolerated Dose in Cancer Phase I Clinical Trials Based on All Toxicities and Individual Genomic Profile.
Chen Z; Li Z; Zhuang R; Yuan Y; Kutner M; Owonikoko T; Curran WJ; Kowalski J
PLoS One; 2017; 12(1):e0170187. PubMed ID: 28125617
[TBL] [Abstract][Full Text] [Related]
37. Optimization of EWOC principle in BLRM design for phase 1 oncology trials.
Guo X; Kent S; Maity A; Zhong W
J Biopharm Stat; 2024 Apr; ():1-17. PubMed ID: 38562014
[TBL] [Abstract][Full Text] [Related]
38. A Bayesian Adaptive Design in Cancer Phase I Trials using Dose Combinations in the Presence of a Baseline Covariate.
Diniz MA; Kim S; Tighiouart M
J Probab Stat; 2018; 2018():. PubMed ID: 30906326
[TBL] [Abstract][Full Text] [Related]
39. Incoherent dose-escalation in phase I trials using the escalation with overdose control approach.
Wheeler GM
Stat Pap (Berl); 2018 Jun; 59(2):801-811. PubMed ID: 29875549
[TBL] [Abstract][Full Text] [Related]
40. Escalation with Overdose Control is More Efficient and Safer than Accelerated Titration for Dose Finding.
Rogatko A; Cook-Wiens G; Tighiouart M; Piantadosi S
Entropy (Basel); 2015 Aug; 17(8):5288-5303. PubMed ID: 27156869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
